Xellia: Hikma beefs up complex manufacturing skillset with Xellia assets
Hikma Pharmaceuticals has bought a raft of US injectable or finished dosage form (FDF) assets from Copenhagen-based Xellia Pharmaceuticals for US$135...
Read full article »
Xellia is a Denmark-based pharmaceutical and life sciences company that develops anti-infective and critical care therapies for the treatment of infectious diseases.
Read more